Home

Primary Examiner: Friedman, Stanley J.
Assistant Examiner:
Attorney: Weiser, Stapler & Spivak

Next ten patents ordered by date:

Method of inhibiting histamine activity with guanidine compounds
5-(3-)SUBSTITUTED-10,11-DIHYDRO-5H-dibenz[b,f]azepines
Hydroxy phenylbutazone derivatives and their preparation
Imidazole insecticides
99M-Technetium labeled tin colloid radiopharmaceuticals
Insecticidal O,S-dialkyl esters of pyridylthio-and-pyridyldithio-phosphoric acids
Control of insects and acarids with O-(2-vinylphenyl)-thiolphosphates
3-(4'-Chlorophenyl)-5-methyl-4,5-dihydro-1,2,4-oxadiazole, its use as an anti-inflammatory agent
3-Heterocyclic thiomethylcephalosporins as antibacterial agents
Guanidino, thioureido and isothioureido derivatives containing imidazole groups

Translate:
En
De
Es
Fr
It
Pt
Ja
Ko
Zh

Title: Drug having an anti-agglutinating effect on platelets and hypocoagulating effect

Do you think this is a good invention? Vote now:

Votes so far: For:(0) Against:(0)
Claims: We claim:

1. A mixture of papaverine or of a physiologically acceptable papaverine salt with a thiosulphate of a physiologically acceptable metal, the two compounds being in respective proportions effective to have an inhibiting effect on hyperadhesion and hyperagglutination on platelets in blood and also have a marked hypocoagulating effect on the kinetic and dynamic coagulability of whole blood.

2. The mixture of claim 1 wherein the metal thiosulphate is magnesium thiosulphate.

3. The mixture of claim 1 wherein the metal thiosulphate is sodium thiosulphate.

4. The mixture of claim 1 wherein the papaverine is papaverine hydrochloride.

5. The mixture of claim 1 wherein the papaverine is papaverine citrate.

6. The mixture of claim 1 wherein the papaverine is papaverine thienyl 2-carboxylate.

7. The mixture of claim 2 which comprises 5 to 20 parts by weight of magnesium thiosulphate for each part by weight of papaverine.

8. The mixture of claim 7 which comprises approximately 10 parts by weight of magnesium thiosulphate for each part by weight of papaverine.

9. A drug composition comprising the mixture of claim 1 in therapeutically effective dosage to have an inhibiting effect on hyperadhesion and hyperagglutination on platelets in blood and also have a marked hypocoagulating effect on the kinetic and dynamic coagulability of whole blood and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition having an inhibiting effect on hyperadhesion and hyperagglutination effect on blood platelets and increasing the hypocoagulating effect on the kinetic and dynamic coagulabilities of whole blood, which comprises the composition of claim 9, in dosage unit between 1000 and 4000 mg of magnesium thiosulphate and between 100 and 400 mg of papaverine, for 10 parts by weight of magnesium thiosulphate for each part by weight of papaverine.

11. The composition of claim 10 wherein the thiosulphate is magnesium or sodium and the papaverine is the hydrochloride, the citrate or thienyl 2-carboxylate.

12. The composition of claim 11 wherein the thiosulphate is magnesium and the papaverine is the hydrochloride, the citrate or thienyl 2-carboxylate.

13. The composition of claim 11 in dosage unit of 0.5 to 5 parts of the thiosulphate and 0.05 to 0.50 parts of papaverine.

14. A drug composition suitable for oral administration comprising the mixture of claim 1 in therapeutically effective dosage in oral administration to have an inhibiting effect on hyperadhesion and hyperagglutination on platelets in blood and also have a marked hypocoagulating effect on the kinetic and dynamic coagulability of whole blood and a pharmaceutically acceptable excipient.

15. A drug composition suitable for rectal administration comprising the mixture of claim 1 in therapeutically effective dosage in rectal administration to have an inhibiting effect on hyperadhesion and hyperagglutination on platelets in blood and also have a marked hypocoagulating effect on the kinetic and dynamic coagulability of whole blood and a pharmaceutically acceptable excipient.

16. An injectable drug solution for parenterally or perfusion administration comprising the mixture of claim 1 dissolved in a sterile injectable solution for administering the composition parenterally or by perfusion, the composition being effective to have an inhibiting effect on hyperadhesion and hyperagglutination on platelets in blood and also have a marked hypocoagulating effect on the kinetic and dynamic coagulability of whole blood.

17. An aqueous solution comprising a mixture of papaverine or a physiologically acceptable salt thereof with a thiosulfate of a physiologically acceptable metal, the two compounds being in respective proportions effective to have an inhibiting effect on hyperadhesion and hyperagglutination on platelets in blood and also have a marked hypocoagulating effect on the kinetic and dynamic coagulability of whole blood.

18. The solution of claim 17 wherein the proportion of papaverine to the thiosulfate is about 1 part to 5 to 20 parts by weight, respectively.

19. A mixture of papaverine with a thiosulphate of a physiologically acceptable metal, the two compounds being in respective proportions effective to have an inhibiting effect on hyperadhesion and hyperagglutination on platelets in blood and also have a marked hypocoagulating effect on the kinetic and dynamic coagulability of whole blood.

20. The method of controlling aggultination agglutination blood platelets and coagulation of blood plasma which comprises treating a patient with a composition comprising the solution defined in claim 17 and a pharmaceutically acceptable carrier in therapeutically effective dosage.

21. The method of claim 20 wherein the administration is oral.
Other info:

Inventors: Raby, Claude (Chaville, FR)
Choay, Jean (Paris, FR)

Application Number: 500888
Filing Date: 1974-08-27
Publication_date: 1976-07-06
Assignee: Choay S.A. (Paris Cedex, FR)
Primary Class(es): 514/307
Other Classes:
US Patent Ref:
Other Refs: Other References: chem. Abst. vol. 65 - 14289-G (1966).
The Merck Index, 7th Ed. (1960), p. 695.